EGFR and non-small cell lung carcinoma: The EGFR-TKI erlotinib is an FDA-approved drug used to treat patients with NSCLC with mutations in the ATP-binding pocket of EGFR (Cohen et al., 2005; Smith, 2005; Nishimura et al., 2015; Lee et al., 2021b).